Tevogen Bio Accelerates AI-Driven Immunotherapy Development with Databricks Partnership

Tevogen Bio Commissions Databricks for AI-Driven Immunotherapy Development

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) has announced a significant partnership with Databricks, Inc. to accelerate the development of PredicTcell, its proprietary AI-driven target prediction model for precision immunotherapy 1

1

. This collaboration marks a crucial step in Tevogen's AI initiative, which aims to transform precision medicine through innovative approaches to drug discovery and healthcare optimization.

PredicTcell: Advancing Precision Immunotherapy

PredicTcell is designed to enhance the modeling of immunologically active HLA+ peptide complexes and predict T cell receptor (TCR) engagement. The partnership with Databricks will focus on two key areas:

1. Predicting immunologically active peptides through machine learning
2. Developing a predictive T cell receptor binding model

Databricks will provide dedicated data engineering support and expertise in building, scaling, and governing data and AI systems to advance these objectives 1

1

.

Strategic Partnerships and AI Integration

The Databricks collaboration represents the third foundational support pillar for Tevogen's AI initiative, complementing existing partnerships with:

• Microsoft Research: Contributing digital infrastructure, scientific research, and AI expertise
• Tevogen Bio: Providing clinical and immunological science and strategic leadership 1

  1

These partnerships underscore Tevogen's commitment to leveraging AI in biotechnology and healthcare innovation.

Tevogen's AI Showcase at AI x Bio Philly

Further demonstrating its leadership in AI-driven biotechnology, Tevogen's Chief Information Officer and Head of Tevogen AI, Mittul Mehta, recently presented at the AI x Bio Philly event 2

2

3

3

. The presentation offered insights into Tevogen's proprietary AI-driven technology for accelerating the discovery and development of off-the-shelf precision T cell therapies.

Mehta's presentation focused on how Tevogen is using computational modeling to predict TCR engagement with immunologically active HLA+ peptide complexes, highlighting the company's innovative approach to immunotherapy development 2

2

3

3

.

Tevogen Bio: A Leader in Immunotherapy and AI

Tevogen Bio is positioning itself as a frontrunner in the integration of AI and biotechnology. The company is developing off-the-shelf, genetically unmodified precision T cell therapies to treat infectious diseases and cancers 2

2

. Key aspects of Tevogen's approach include:

• Harnessing CD8+ cytotoxic T lymphocytes for immunotherapy
• Focusing on patient accessibility through advanced science and innovative business models
• Owning key intellectual property assets, including AI-related patents

The company has reported positive safety data from its proof-of-concept clinical trial and is driven by a team of experienced industry leaders and scientists 2

2

.

Future Outlook and Potential Impact

Tevogen's AI-driven approach to immunotherapy development has the potential to significantly impact the healthcare and biopharmaceutical industries. By leveraging partnerships with leading technology companies and focusing on AI-driven solutions, Tevogen aims to accelerate drug discovery, optimize healthcare delivery, and increase access to high-quality essential medicines 1

1

.

As the company continues to expand its efforts in artificial intelligence and develop additional product candidates, it is poised to play a crucial role in shaping the future of precision medicine and biotechnology.